- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
BioAlliance Pharma SA, a specialty pharmaceutical company focused on the development and marketing of innovative therapeutics targeting cancer, HIV, opportunistic infections and drug resistance, today announced its revenues for Q3 2007.
"Q3 2007 will go down in BioAlliance's history as a particularly significant quarter," said Nicolas Fellmann, CFO at BioAlliance Pharma. "The launch of BioAlliance's first product, Loramyc®, means the company is generating its first revenues by selling directly on the French market. We are implementing our international sales strategy and generating income through our agreement with Par Pharmaceutical in the USA, the upfront payment for which is being accounted for over two years. The two agreements already signed (with Par pharmaceutical in the USA and the creation of the SpeBio joint venture in Europe) have already brought in EUR 19 million to which we have added the EUR 40 million raised from qualified investors this summer."
"BioAlliance Pharma today has the financial resources to accelerate its development," said Dominque Costantini, CEO of BioAlliance. "With the first revenues derived from a product developed from start to finish by BioAlliance and with our partnership agreements, we are demonstrating the robustness of our specialty pharma model and its capacity to add value. We are determined to become a leading player in Europe."
Consolidated revenue details
| In thousands of euros,
excluding sales tax, IFRS
|Q3 2007||Q3 2006|
|Sales of Loramyc®||259||-|
|Par Pharmaceutical agreement||1380||-|
|Provision of services||123||102|
In compliance with IAS 18 standards, the revenues from upfront payments received in connection with partnership agreements have been accounted for over a period of time:
Services provided by BioAlliance Pharma to Eurofins-VIRalliance (EVI,Inc.) amounted to EUR 123,000 against EUR 102,000 in Q3 2006.
Q4 revenues will be announced on January 30, 2008, and full year 2007 results on February 29, 2008.
About BioAlliance Pharma SA
BioAlliance Pharma SA (Euronext Paris: BIO) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapeutics targeting cancer, HIV, opportunistic infections and drug resistance.
The Company is currently conducting 3 phase III clinical trials on innovative products. Two products are based on the Lauriad® mucoadhesive technology, which allows an early and prolonged release of therapeutic agents at the site of the disease: one authorized product in France and two clinical international phase III trials ongoing (Loramyc® and acyclovir Lauriad®). One product is based on the Transdrug® nanoparticle technology designed specifically for intracellular targeting: one international phase III trial ongoing on primary liver cancer (doxorubicin Transdrug®). The company develops also a New Entities program focused on new targets in oncology and HIV.
The company concluded two strategic partnerships in 2007 to sell its Loramyc(R) product in Europe and in the US. BioAlliance Pharma has just announced the launch of Loramyc® on the French market.
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements please refer to the Risk Factors (Facteurs de Risque) section of the reference document approved by the AMF on 6 April 2007 under the number R. 07-031, which is available on the AMF website http://www.amf-france.org or BioAlliance Pharma S.A.'s website http://www.bioalliancepharma.com .
For more information, please click here
President and CEO
Tel: +33 1 45 58 76 01
Chief Financial Officer
Tel: +33 1 45 58 71 00
Copyright © BioAlliance Pharma SAIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
The NanoWizard® AFM from JPK is applied for interdisciplinary research at the University of South Australia for applications including smart wound healing and how plants can protect themselves from toxins July 26th, 2016
Accurate design of large icosahedral protein nanocages pushes bioengineering boundaries: Scientists used computational methods to build ten large, two-component, co-assembling icosahedral protein complexes the size of small virus coats July 25th, 2016
Nanometrics Reports Second Quarter 2016 Financial Results July 26th, 2016
Nanobiotix revenue for Q2 2016 July 14th, 2016